erlotinib drug pathway erlotinib pharmacodynamics pathway 2011-06-14T03:34:08Z PW:0000874 SMP:00472 The pathway of erlotinib-target interaction and of the biochemical or physiological responses to drug. Erlotinib is the second (after gefitinib) selective inhibitor of EGFR whose mutations within the tyrosine kinase domain have been associated with hyperactive epidermal growth factor signaling in non-small cell lung cancers. Genetic variations can cause differences in the response of the organism to the drug. pathway vpetri